Association of Biomarker‐Matched Therapy With Survival in Non‐Small Cell Lung Cancer by Surgical Status and Sequencing Specimen Source: A Cohort Study From MSK ‐ CHORD
International Journal of Cancer · 08.11.2026
DOI: 10.1002/ijc.70775 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift International Journal of Cancer, online erschienen am 08.11.2026. Verfasst von Jiantong Sun und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, …. Die Arbeit nennt 18 Literaturangaben. Gefördert von: "Qimingxing" Research Fund for Young Talents, National Natural Science Foundation of China, Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Real‐world analyses of biomarker‐matched therapy (BMT) are complicated when sequencing, surgery, and treatment occur at different times. We evaluated associations between BMT and overall survival (OS) by surgical status at sequencing and specimen source and examined treatment timing. Among 6624 patients with non‐small cell lung cancer in MSK‐CHORD, 5467 with an operational opportunity for BMT formed the propensity‐weighted cohort. OS was measured from first sequencing; surgical status reflected surgery completed by that date. Fixed‐exposure analyses used stabilized inverse probability of treatment weights. The overall HR was 1.10 (95% CI 1.01–1.20). HRs were 1.40 (1.23–1.59) with surgery completed by sequencing and 0.83 (0.74–0.93) without surgery, and 1.30 (1.15–1.47) for primary‐tumor specimens and 0.80 (0.71–0.91) for metastatic‐site specimens; interaction tests were significant (all p < 0.001). Time‐dependent HRs were 2.06 (1.76–2.42) and 1.12 (0.99–1.26) by surgical status, and 1.76 (1.52–2.03) and 1.14 (1.01–1.30) by specimen source. Landmark analyses did not retain the lower fixed‐exposure estimates in the no‐surgery and metastatic‐specimen strata. In a 685‐patient non‐MSK metastatic cohort, HRs were 0.88 (0.63–1.25) for primary‐tumor sequencing and 0.64 (0.48–0.84) for metastatic‐site sequencing. BMT–OS associations were sensitive to clinical context and treatment timing, underscoring temporal alignment of sequencing, surgery, treatment initiation, and follow‐up.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Thoracic Surgery, Institute of Thoracic Oncology, Frontiers Science Center for Disease-Related Molecular Network, West China Hospital, Sichuan University, Chengdu, Sichuan, China.
- West China Collaborative Innovation Center for Early Diagnosis and Multidisciplinary Therapy of Lung Cancer, Sichuan University, Chengdu, Sichuan, China.
- West China Medical School, Sichuan University, Chengdu, Sichuan, China.
ORCID-Profile: Jiantong Sun, Lunxu Liu
Förderung
- "Qimingxing" Research Fund for Young Talents
- National Natural Science Foundation of China
- Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
- 1.3.5 Project for Disciplines of Excell, West China Hospital, Sichuan University
Zitieren
APA
Sun, J., Xian, L., Yang, Z., Ku, Y., Liu, M., Wu, D., Wei, S., & Liu, L. (2026). Association of Biomarker‐Matched Therapy With Survival in Non‐Small Cell Lung Cancer by Surgical Status and Sequencing Specimen Source: A Cohort Study From MSK ‐ CHORD. International Journal of Cancer. https://doi.org/10.1002/ijc.70775
Vancouver
Sun J, Xian L, Yang Z, Ku Y, Liu M, Wu D, et al. Association of Biomarker‐Matched Therapy With Survival in Non‐Small Cell Lung Cancer by Surgical Status and Sequencing Specimen Source: A Cohort Study From MSK ‐ CHORD. International Journal of Cancer. 2026. doi:10.1002/ijc.70775
BibTeX
@article{Sun2026,
author = {Sun, Jiantong and Xian, Longjun and Yang, Zhenyu and Ku, Yin and Liu, Mao and Wu, Dongsheng and Wei, Shiyou and Liu, Lunxu},
title = {Association of Biomarker‐Matched Therapy With Survival in Non‐Small Cell Lung Cancer by Surgical Status and Sequencing Specimen Source: A Cohort Study From MSK ‐ CHORD},
journal = {International Journal of Cancer},
year = {2026},
doi = {10.1002/ijc.70775}
}
EUVIMED